Claudia Kloth
Nanoscience and Nanotechnology
Benitec Biopharma
Australia
Biography
Dr. Kloth leads the manufacturing efforts for clinical and pre-clinical gene therapy vectors for Benitec. Dr. Kloth has over 20 years of cGMP manufacturing and process development experience in therapeutics, including adeno-associated virus (AAV) vectors used by Benitec in its hepatitis C, hepatitis B, AMD and OMPD programs. Prior to joining Benitec, Dr. Kloth led the Process Development group at the CMO Lonza Viral Therapeutics and successfully developed, optimized and transferred robust viral-based products (Ad5, AAV, lentivirus) to cGMP manufacturing. She contributed to enabling process scalability from small to large manufacturing scale of over 1000L using disposable technologies. She was also instrumental in establishing a scalable AAV process production platform. During her tenure at Medarex Inc. as a process development specialist, she guided the process transfer and process validation activities of its most advanced anti-melanoma antibody product Ipilimumab, aka Yervoy (Bristol-Myers Squibb) approved by the FDA in 2011. Dr. Kloth earned her Ph.D. in Biotechnology Engineering from the Technical University Berlin, Germany. She joined Benitec in April 2015 and is based in New Jersey, U.S.A.
Research Interest
Nanoscience and Nanotechnology
